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Background
Juvenile idiopathic arthritis (JIA) is sometimes associated
with growth impairment due to inflammation and/or
steroid treatment. Biologics allow a better control of
inflammation and may therefore have a positive effect
on growth.
Aim
To assess growth of JIA children on biologics.
Methods
JIA patients followed in one reference center, who were
prebupescent at onset of biologic treatment, were
included. We collected data about their growth and
their disease (course, treatments, activity). Heights were
expressed in standard deviations (SD) corrected with
target height, at disease onset, at onset of biologics and
at last follow-up.
Results
100 patients were included. 29% were systemic. Mean
age and height were 4.26 years (0.7; 13.7) and 0.31 SD
(-2.47; 5.46) respectively at disease onset, 7.1 years (1.6;
15.7) and -0.24 SD (-3.63;2.90) at onset of biologics
(p<0.05), 11 years (2.3;19.5) and -0.15 SD (-4.95;3.52) at
last follow-up. 93 had received anti-TNFa,3 5a n t i - I L 1 ,
12 anti-IL-6 and 9 CTLA4-Ig. 45% had an active disease.
More than one biological agent was statistically linked
with poor growth. At last follow-up, 10 children had a
growth delay and 6 were treated with growth hormone.
Conclusion
Growth delay was observed before biologics were
started. On biologic treatment, growth velocity normal-
ized, however there was no correction of growth delay.
The discrepancy with previous studies, which showed a
g r o w t hr e s t o r a t i o no na n t i - T N F ,m i g h tb el i n k e dt oa
higher proportion of systemic and severe polyarticular
JIA patients. In a subset of patients, growth hormone
treatment has to be discussed even at the era of
biologics.
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